Ventures
Invest in breakthrough healthtech solutions that transform patients' lives.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.
a highlight from our portfolio

Angiogenesis Analytics

PEP Health
Allergios revolutionizes allergy diagnosis by directly visualizing the allergic response in patient blood, offering a more accurate alternative to current tests like skin prick and IgE blood tests. Additionally by analyzing how blood serum reacts to allergens. With its disposable chip, optical reader, and AI-based analysis software, Allergios helps millions of allergy sufferers worldwide access timely and effective treatment options.

NLC's venture, Profionics, advances Cardiff University's sepsis research with a biomarker test combining AI, gene expression, and metabolic analysis for rapid, accurate diagnosis. This test, which works in under 30 minutes with a drop of blood, surpasses traditional methods by quickly identifying those needing antibiotics and reducing unnecessary use, thus combating antimicrobial resistance and saving lives. Particularly impactful in neonatal care, it ensures timely detection critical for newborn survival. Founded by NLC, Cardiff University, and CEO Darren Fergus, Profionics leverages extensive research and a blood sample BioBank, positioning itself as a leader in host response diagnostic testing.

Heat2Move offers a revolutionizing approach to chronic back pain treatment. Unlike traditional methods relying on medications or heat patches, Heat2Move combines blue light and infrared warmth to enhance blood flow and muscle repair. This innovative solution provides therapists and patients with a new tool for managing chronic pain effectively. With its potential to make a significant impact on treatment options, BlueTouch offers hope for those suffering from back pain worldwide.

Intuescope, develops advanced tools to make endoscopy and colonoscopy procedures faster and safer. Despite being gold standard tests, traditional scopes have changed little over 40 years and often miss abnormalities. Intuescope's innovations aim to reduce procedure time, enhance detection accuracy, and support doctors with more automation, addressing the growing need for efficient and reliable endoscopic solutions.

Nicolab tackles the challenge of stroke diagnosis and treatment by offering computational support through their portfolio of six algorithms. These algorithms analyze radiological images of acute stroke patients, providing fast and objective interpretation for physicians. With stroke affecting millions annually and significant economic burdens, Nicolab's solution improves decision-making speed and accuracy, allowing clinicians to assess stroke severity objectively and make timely treatment decisions.

Rare diseases often lead to years of diagnostic odyssey and immense patient suffering. Therefore Genorare is set to dramatically shorten this diagnostic journey for individuals with rare diseases. Genorare's platform enables real-time, secure analysis of genomic, clinical, and phenotypic data using Large Language Models, predictive analytics, and Fully Homomorphic Encryption. A key innovation is the use of Fully Homomorphic Encryption, a next-generation privacy technology that allows for advanced analysis while ensuring patient data remains completely secure, promising a new standard of care for the rare disease community.

Karla Therapeutics is exploring an approach, treating mental disorders by leveraging our immune system. Neurodevelopmental disorders like ADHD and OCD are increasingly prevalent, yet treatment options often have side effects and limited effectiveness. By bridging between the immune system and mental health, Karla aims to revolutionize treatment methods. Their research focuses on a specific protein identified by top-tier immunologists, showing promising results in early experiments for OCD, anxiety, and ADHD.

BiteOn has devised a breakthrough in dental implants: personalized implants tailored to each patient's jawbone structure. Traditional bone graft procedures are costly and painful, often extending treatment time by six months. BiteOn's solution eliminates the need for bone grafts by designing implants based on 3D scans of the patient's mouth. This innovation promises quicker, less painful, and more successful dental replacements, offering hope to patients previously unable to undergo traditional procedures.

Our impact
Explore our 2024 Impact report

Invest in a portfolio of companies





